Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Incidence of Autoimmune pulmonary alveolar proteinosis
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Autoimmune pulmonary alveolar proteinosis

1 evidence topic · 1 source

Japanese registry: minimum incidence and prevalence

“Autoimmune PAP represented 89.9% of cases and had a minimum incidence and prevalence of 0.49 and 6.2 per million, respectively.” (opens the source at this quote in a new tab)